61 results about "Neutrophilic Granulocyte" patented technology

The invention discloses a reagent for classifying leukocytes, which can be used for classifying leukocytes into five groups corresponding to lymphocytes, monocytes, eosinophilic granulocytes, neutrophilic granulocytes and basophilic granulocytes. The reagent comprises a buffering agent and a hemolytic agent, wherein the hemolytic agent comprises at least two types of betaine type amphoteric surfactants. The reagent can be applied in wide pH value and temperature ranges, does not damage the leukocytes and can be used for accurately classifying white blood cells.

The invention relates to application of arctigenin in preparation of medicines for preventing and treating bone marrow suppression. The arctigenin has unexpected activities for enhancing immunity, promoting hemopoiesis and many other aspects. The animal in-vivo test proves that the arctigenin can obviously increase the quantity of leucocytes after chemotherapy, especially the quantity of neutrophilic granulocytes. Thus, the arctigenin is an active component capable of resisting side reactions of chemotherapy and enhancing the chemotherapeutic effect of tumors, and has very important meanings for prolonging the life time of cancer patients and improving the life quality of cancer patients.

The invention relates to a method for preparing a gene therapy medicine for novel corona virus 2019. The method comprises the following steps: according to an nCoV2019 (novel corona virus 2019) genome, screening an siRNA (small interference ribonucleic acid) sequence with an RNA interference effect, and performing synthesis by using a nucleic acid synthesis method; and preparing synthesized nCoV2019siRNA into lipid nanoparticles LHNPs, and compounding LHNPs or nCoV2019siRNA with a spray, so as to obtain a gene therapy product with inhalation administration. When reaching target cells, siRNA isdegraded since an siRNA antisense strand which is generated under the action of inherent and stress boosted helicase and endonuclease / exonuclease is combined with homologous RNA and / or mRNA (messenger ribonucleic acid). In addition, type-I interferon, IL-6, TNFa (tumor necrosis factor a) and the like can be generated under stimulation of double-strand siRNA and cellular immunity can be mediated,it is known that type-I interferon has antiviral immunity, IL-6 is capable of inducing hyperplasia of immune globulin and T cells, and the TNFa is capable of promoting infection resistance of neutrophile granulocyte, inducing apoptosis of virus infected cells and thus inhibiting virus hyperplasia, so that in addition to virus prevention of RNA interference, antibacterial antiviral immunity of cellfactors, immune cells and immune globulin can be also triggered, and in addition, the medicine can be efficiently and rapidly synthesized, and is easy in short-term application to treatment or prevention.

The invention relates to use of 1-ethyl-3, 7-dimethylxanthine in preparing a medicine for treating pneumonia and belongs to the technical field of medicines. The invention provides use of 1-ethyl-3, 7-dimethylxanthine or a salt thereof in preparing a medicine for treating pneumonia. Pharmacological experiment results show that various dosage forms of the 1-ethyl-3, 7-dimethylxanthine can obviously inhibit pneumonia caused by infection of viruses, bacteria and mycoplasmas, reduce a lung index of infected mice, reduce levels of inflammatory factors such as TNF-alpha, IL-8, IL-10 and IL-17, improve a level of IFN-gamma and improve count of leukocyte and neutrophile granulocyte in peripheral blood, which indicate that the 1-ethyl-3, 7-dimethylxanthine has a strong anti-pneumonia effect.

The invention relates to application of a compound as shown in the general formula (I) or pharmaceutically acceptable salt in the preparation of medicines for preventing and / or treating cytopenia of patents who will receive, is receiving or has received chemotherapy and drug therapy. In the general formula, R1, R2 and R3 can be the same or different and respectively and independently represent H or C1-C3 alkyl group. In comparison with common clinical drugs (such as G-CSF) for increasing haemocyte count for those who receive chemotherapy, the compound of the invention can remarkably increase hemocyte in those who receive chemotherapy, especially increase leucocyte, in particular the number of neutrophile granulocyte and monocyte. The compound of the invention has a good clinical prospect.

The present invention relates to a mutant G-CSF fusion protein. The mutant G-CSF fusion protein is a fusion protein having the activity of stimulating the proliferation of neutrophilic granulocytes, and having a basic structure of G-CSF / carrier protein or carrier protein / G-CSF; wherein the G-CSF moiety comprises multipoint substitutions thus resulting in changes in biological activity and binding affinity. Compared with existing products, the mutant G-CSF fusion protein in the present invention has longer half-life and higher biological activity. Administration of the pharmaceutical preparation containing this mutant G-CSF fusion protein could be used in the treating neutropenia.

Disclosed are an inflammation-targeted neutrophil granulocyte drug delivery system and use thereof, wherein the drug delivery system includes neutrophil granulocytes and a therapeutic substance or a detectable substance loaded into the neutrophil granulocytes or onto the surface of the neutrophil granulocytes in a direct or indirect way. By using the neutrophil granulocytes as a carrier of a drug, the drug is actively targeted to an inflammatory site, thereby increasing the drug concentration at the inflammatory site. Under the stimulation of cytokines, the neutrophil granulocytes arriving at the inflammatory site are abnormally activated, disintegrate rapidly, and die in the way of “Neutrophil extracellular traps (NETs)”. This helps to rapidly release the loaded drug to the targeted site, so as to improve the therapeutic effect and reduce the toxic and side effects.